Astronauts find it difficult to maintain a natural circadian rhythm and generally complain about their sleep. A new project will examine the differences between human sleep patterns on earth and in space using an ear EEG.
Apnimed’s AD109 has the potential to be the first oral pharmacologic that treats OSA airway obstruction at night.
“This study reinforces the potential of AD504 as a follow on to our lead product AD109,” says Larry Miller, MD, Apnimed CEO, in a release.
First published in 2018, the book Understanding Sleeping Pills by Wallace B. Mendelson, MD, has recently been updated.
Results from the Wake Up America survey, conducted by The Alliance for Sleep and sponsored by Idorsia, will be presented at SLEEP 2022.
ResMed today announced a definitive agreement to acquire privately held MEDIFOX DAN, a German out-of-hospital software solutions company.
Medtrade, a medical equipment trade event, will take place at the Kay Bailey Hutchison Convention Center in downtown Dallas.
The Young Investigators Research Forum is an annual training program that was first launched in 2009 for sleep researchers.
Incannex characterized the pre-investigational new drug application (pre-IND) meeting about IHL-42X as “highly constructive.”